A study showed that the expression level of CD161 mRNA in CD4+ cells in peripheral blood of tumor patients was significantly higher than that of healthy people, and the frequency of CD4+CD56− cells expressing CD161 in CD4+ T cells in peripheral blood and tumor-involved sites of cancer patients increased. This evidence concerns the gene CD4 and cancer.